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Abstract
Despite remarkable advances in the knowledge of molecular biology and treatment, ovarian cancer remains the leading cause 
of death from gynecologic cancer. In the last decade, there have been important advances both in systemic and surgical treat-
ment. However, there is no doubt that the incorporation of PARP inhibitors as maintenance after the response to platinum-
based chemotherapy, first in recurrent disease and recently also in first line, will change the natural history of the disease.
The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of ovarian cancer, 
and to provide evidence-based recommendations for clinical practice.
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Introduction
Epithelial ovarian cancer (OC) remains the 5th cause of 
death in women and the first cause of death due to gyneco-
logical cancer. In the last two decades, we have assisted 
to achievements in the knowledge of molecular biol-
ogy, surgical outcome, chemotherapy administration, and All authors are members of SEOM and GEICO (Grupo Español 
de Investigación en Cáncer de Ovario) and this manuscript is 
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implementation of antiangiogenic therapy that have trans-
lated into clinically significant improvements in the time of 
disease control and overall survival in some cases. More 
recently, the incorporation of Poly ADP Ribose Polymerase 
(PARP) inhibitors as maintenance after response to plati-
num-based chemotherapy seems to start changing the natural 
history of the disease and the aim of decreasing the mortality 
is becoming a reality. This SEOM guideline is providing 
updated evidence-based recommendation for the current 
treatment of ovarian, primary peritoneal and fallopian tube 
cancer, globally considered as OC along the guideline.
Methodology
This guideline has been developed with the consensus of ten 
oncologists, with high expertise in OC treatment, from the 
cooperative group GEICO (Spanish Group for Investigation 
in Ovarian Cancer) and SEOM (Spanish Society of Medi-
cal Oncology). To assign a level and quality of evidence 
and a grade of recommendation to the different statements 
of this treatment guideline, the Infectious Diseases Society 
of America-US Public Health Service Grading System for 
Ranking Recommendations in Clinical Guidelines was used.
Diagnosis and staging
Early-stage OC is frequently associated to non-specific 
symptoms, but in late-stages ascites, abdominal disorders 
and/or pleural effusion are common. In women with symp-
toms suggestive of OC, physical examination, laboratory 
testing with CA 125 and pelvic ultrasonography are rec-
ommended at a first level [II, A]. High levels of HE4 iden-
tify malignancy with a similar sensitivity than CA 125, but 
with higher specificity. Both CA 125 and HE4 are included 
in the Risk Ovarian Malignancy Algorithm (ROMA), used 
for calculating the risk of malignancy of adnexal masses.
In patients with presumed OC, computed tomography 
(CT) imaging of the thorax, abdomen and pelvis will 
define the extent of the disease and provide information to 
plan treatment options [II, A]. Magnetic resonance imag-
ing (MRI) and Positron Emission Tomography (PET)-
CT are not included in the routine preoperative staging 
but could improve the accuracy of the evaluation of the 
advanced disease [II, B]. Laparoscopic surgery is a main-
stay not only in staging of OC but also in pathological 
diagnosis [II, B]. FIGO 2014 is the staging system cur-
rently recommended [1] (Table 1).
Table 1  2014 FIGO staging system for ovarian, fallopian tube, and peritoneal  cancer1
Stage I Tumour confined to ovaries or fallopian tube(s)
 IA Tumour limited to one ovary (capsule intact) or fallopian tube; no tumour on ovarian or fallopian tube surface; no malignant cells 
in the ascites or peritoneal washings
 IB Tumour limited to both ovaries (capsules intact) or fallopian tubes; no tumour on ovarian or fallopian tube surface; no malignant 
cells in the ascites or peritoneal washings
 IC1 Tumour limited to one or both ovaries or fallopian tubes, with surgical spill
 IC2 Tumour limited to one or both ovaries or fallopian tubes, with capsule ruptured before surgery or tumour on ovarian or fallopian 
tube surface
 IC3 Tumour limited to one or both ovaries or fallopian tubes, with malignant cells in the ascites or peritoneal washings
Stage II Tumour involves one or both ovaries or fallopian tubes with pelvic extension or primary peritoneal cancer
 IIA Extension and/or implants on uterus and/or fallopian tubes and/or ovaries
 IIB Extension to other pelvic intraperitoneal tissues
Stage III Tumour involves one or both ovaries or fallopian tubes, or primary peritoneal cancer, with cytologically or histologically con-
firmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes
 IIIA1 Positive retroperitoneal lymph nodes only (cytologically or histologically proven)
  IIIA1(i) Metastasis up to 10 mm
  IIIA1(ii) Metastasis more than 10 mm
 IIIA2 Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes
 IIIB Macroscopic peritoneal metastasis beyond the pelvis up to 2 cm in greatest dimension, with or without metastasis to the retroperi-
toneal lymph nodes
 IIIC Macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension, with or without metastasis to the 
retroperitoneal lymph nodes (includes extension of tumour to capsule of liver and spleen without parenchymal involvement of
either organ)
Stage IV Distant metastasis excluding peritoneal metastases
 IVA Pleural effusion with positive cytology
 IVB Parenchymal metastases and metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of 
the abdominal cavity)
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Pathology and biomarkers
According to the WHO classification, there are five major 
subtypes of epithelial ovarian carcinoma: high-grade serous 
(HGSC), low-grade serous (LGSC), clear cell (CCC), endo-
metrioid (EC), and mucinous (MC). The use of an immuno-
histochemical (IHC) panel including Wilms Tumor 1 (WT1), 
p53, progesterone receptor (PR), and Napsin A (NAPSA) has 
been suggested to assist in the diagnosis of cases in which 
the histological type is difficult to establish [2] [II, A]. The 
OC subtypes differ not only in IHC expression but also in 
molecular features (Table 2). Furthermore, in non-mucinous 
tumors, a study of germinal (and somatic if possible) BRCA 
mutation must be completed after pathological diagnosis 
due to its implications on hereditary counseling, prognostic 
information, and therapeutic strategy [I, A]. For therapeutic 
decisions, it would be desirable to have also information on 
tumor homologous recombination (HR) status [I, A].
Early stages
Surgery
The treatment for early-stage OC (stages I-II) consists of 
a staging surgery that includes hysterectomy with bilateral 
salpingo-oophorectomy, bilateral pelvic and para-aortic lym-
phadenectomy, omentectomy, random peritoneal biopsies, 
peritoneal washing, and careful inspection and palpation of 
all peritoneal surfaces, the serosa of the entire digestive tract 
and the bowel mesentery [II, A]. Lymph node dissection can 
safely be omitted in grade I mucinous tumors. Both open and 
laparoscopic approaches are acceptable as long as an expe-
rienced gynaecologic oncologist performs all the procedure 
[3] [II, A]. In patients referred to after incomplete surgery, a 
re-staging procedure should be offered [III, A].
Fertility-sparing surgery, based on a unilateral salpingo-
oophorectomy and complete surgical staging can be safely 
offered to all stage IA, and IC1 low-grade ovarian carcino-
mas [II, A].
Adjuvant treatment
Adjuvant platinum-based chemotherapy after staging 
surgery is indicated in high-risk early stages (IA/B high 
grade, IC-IIA) [I, A]. The benefit is uncertain and should 
be discussed on individually in: Grade 1–2 EC stage IB/IC, 
MC with expansile invasion stage IB/IC, MC with infiltra-
tive invasion stage IA, LGSC stage IB/IC, and CCC stage 
IA-IC1 [4].
The recommended regimen is paclitaxel-carboplatin, 
but single-agent carboplatin is also considered a reason-
able option [I, A]. 6-cycle regimen is recommended in 
HGSC, but the optimal duration remains controversial in 
the rest of histologic subtypes, in which three cycles can 
be accepted [4] [I, A].
Advanced disease: front‑line treatment
Cytoreductive surgery
Cytoreductive surgery plays a crucial role in the treatment 
of advanced OC (stages III and IV). The presence of visi-
ble residual disease after cytoreduction is a major prognos-
tic factor with an important negative impact on survival. 
Thus, the goal must be to obtain a complete cytoreduction 
[II, A]. In this context surgical effort must be maximal and 
may include histerectomy, double anexectomy, omentec-
tomy, extensive peritonectomy, bowel resection or excision 
of any enlarge nodes. Due to the recent results of Lion 
trial lymphadenectomy in primary completely debulked 
advanced OC with clinically negative lymph nodes is not 
further recommended [5] [I, A].
Several studies and meta-analysis suggest that the 
expertise of the surgeon is of utmost importance in the out-
comes and thus the recommendation is that patients should 
be operated in highly experienced centers [6] [II, A].
Table 2  Immunohistochemical 
panel for diagnosis of the 
subtypes of ovarian cancer
HGSC high-grade serous carcinoma, LGSC low-grade serous carcinoma, CCC clear cell carcinoma, EC 
endometrioid carcinoma, MC mucinous carcinoma, WT1 Wilms Tumour 1, ER estrogen receptor, NAPSA 
naspin A, N/A not applicable
Pax8 WT1 P53 ER NAPSA Ki67
HGSC  +  +  + (diffuse)  + −/ + High
LGSC  +  + –  + – Low
CCC  + – −/ + –  + N/A
EC  + – –  + −/ + N/A
MC −/ + – – −/ + (focal) – N/A
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Neoadjuvant chemotherapy
The EORTC55971 trial and the CHORUS trial showed a 
similar progression-free survival (PFS) and overall survival 
(OS) for patients with stage IIIC or IV disease receiving 
neoadjuvant chemotherapy (NACT) and interval debulk-
ing surgery (IDS) compared with primary debulking sur-
gery (PDS). In spite of these non-inferiority results, these 
aforementioned trials have been criticized because of the 
median OS, mean operative time and low rates of optimal 
cytoreduction.
Therefore, both approaches (PDS or NACT followed by 
IDS) can be considered valid, although PDS remains as the 
preferred primary treatment when complete cytoreduction 
is feasible and patient is operable [4] [I, A].
Chemotherapy regimen and route of administration
Standard post-operative treatment in advanced OC consists 
of a combination of carboplatin (AUC 5–6) and paclitaxel 
(175 mg/m2) every 3 weeks for six cycles [I, A].
Incorporation of weekly chemotherapy into first-line 
treatment does not improve PFS or OS in the population of 
western countries [7]. Moreover, single agent carboplatin 
or weekly chemotherapy could have even worse outcomes 
in vulnerable elderly patients, as shown by EWOC-1 trial, 
so that 3-weekly regimen remains the standard for all OC 
populations [I, A].
Three large randomized studies (GOG 104, GOG 114, 
and GOG 172) and one meta-analysis have found clinically 
significant improvements in PFS and OS with intraperitoneal 
(IP) chemotherapy [8]. However, in the GOG 252 trial the 
duration of PFS was not significantly increased with either 
IP regimen when bevacizumab was incorporated in all arms, 
and IP cisplatin arm was associated to higher toxicity [9]. 
Therefore, and according to last ESMO-ESGO consensus, 
currently IP chemotherapy is not a standard of care [4] [III, 
A]. Nevertheless, it could still be considered in selected 
patients (stage III, < 1 cm residual disease) as long as beva-
cizumab is not used [I, B].
A randomized phase III trial evaluating hyperthermic 
intraperitoneal chemotherapy (HIPEC) after IDS showed a 
better OS for HIPEC arm. However, this trial has received 
significant methodological criticisms, so HIPEC cannot be 
considered a standard treatment and should not be offered 
out of clinical trials [4] [I, C].
Bevacizumab
Two large randomized studies (GOG 218 and ICON 7) have 
reported that bevacizumab added to the initial chemotherapy 
followed by a maintenance period improves PFS in com-
parison with standard chemotherapy alone [10, 11]. None 
of these trials showed an OS benefit in the overall study 
populations but post hoc subgroup analysis indicated statisti-
cally significant OS benefit in patients with stage IV disease 
in GOG 218 (18) and patients at high risk of progression 
(defined as FIGO stage III with > 1 cm residual disease after 
PDS or stage IV) in the ICON7 trial.
Bevacizumab (15 mg/kg or 7.5 mg/kg every 3 weeks for a 
maximum of 15 months) should be considered in addition to 
carboplatin and paclitaxel, and it is especially recommended 
in patients with stage III and residual disease or stage IV 
[I, A].
Maintenance treatment with PARP inhibitors
Four randomized phase III trials (SOLO-1, PRIMA, 
PAOLA-1 and VELIA) have shown that maintenance treat-
ment with PARP inhibitors (PARPi) after response to front-
line platinum-containing regimens increased significantly 
the median PFS in HGSOC [12–15]. Table 3 summarizes 
differences in the design between these trials and the results 
in the ITT and the different biomarker subgroup populations. 
All trials have shown a remarkable and unprecedented ben-
efit in BRCAmut. In addition, PAOLA-1 and PRIMA dem-
onstrated also a significant benefit in HR deficient (HRD) 
population. Finally, only PRIMA showed a benefit in the 
HR proficient (HRP) subgroup although of lesser magni-
tude. The benefit observed with PARPi is sustained along 
the follow-up as demonstrated by the impact on PFS2, as 
well as by the results after a 5-year follow-up of the SOLO-1 
showing that almost 50% of patients remain progression-free 
in contrast to 21% in the control arm.
Based on these results, olaparib (with or without beva-
cizumab) or niraparib after partial or complete response to 
first-line platinum-based chemotherapy are highly effective 
in BRCA -mutated patients and strongly recommended [I, A].
According to PAOLA-1 and PRIMA results, niraparib 
or olaparib-bevacizumab are also highly recommended 
for patients with HRD tumors [I, A]. In the HRP subgroup 
maintenance with niraparib can also be considered although 
bevacizumab remains as a reasonable alternative [I, B].
Recurrent disease
Approximately, 80–85% of patients with advanced OC will 
relapse in the first 10 years after the diagnosis [16]. When 
planning treatment for recurrent disease, first considera-
tions must be willingness of the patient to receive further 
therapy and performance status (PS). Next step is to decide 
if platinum might be the best option taking into account 
the following factors. Conversely, the traditional and arbi-
trary classification as platinum-sensitive and platinum-
resistance has been abandoned during the Fifth Ovarian 
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Cancer Consensus Conference (OCCC) of the GCIG and 
the ESMO-ESGO consensus [4, 17].
Factors to consider when selecting therapy
Depending on the tumour: Site and extension of the dis-
ease, histological subtype, BRCA mutation status.
Depending on the patient: Treatment-free interval. Plat-
inum-free interval (TFIp) has classically been considered a 
predictive factor of response to platinum-rechallenge. Also 
TFInp (non-platinum) or TFIb (biological) should be con-
sidered as well as number of previous therapies, residual 
toxicity, patient preferences and comorbidities with special 
attention to geriatric population [17].
Surgery for relapsed ovarian cancer
The randomized Desktop III trial has shown a significant 
OS benefit of surgery at relapse among patients accom-
plishing AGO score. Therefore, surgery should be rec-
ommended for patients with TFIp > 6 months, no residual 
disease after first surgery, good PS (0–1), and absence or 
less than 500 ml of ascites [18] [I, A]. In addition, PET-CT 
could improve the selection of candidates for secondary 
cytoreduction [19] [II, B].
Systemic treatment when platinum might be 
the best option
A platinum-based combination (with paclitaxel, gemcitabine 
or pegylated liposomal doxorubicin -PLD-) is associated 
with a longer PFS and OS compared to single-agent plati-
num. None of these combinations can be considered superior 
in terms of efficacy; the doublet selection should be based 
on the toxicity profile.
A randomized phase III trial of bevacizumab combined 
with carboplatin-gemcitabine, in patients in first relapse 
who have not been treated with antiangiogenic therapy, has 
shown a benefit in response rate (RR) and PFS [20]. The 
combination of bevacizumab with carboplatin and paclitaxel 
in this setting has also shown improvement in PFS [21]. 
Recently, the combination carboplatin-PLD and bevaci-
zumab have shown benefit in PFS and OS over carboplatin-
gemcitabine and bevacizumab [22].
Three PARP inhibitors (olaparib [23] niraparib [24] 
and rucaparib [25]) have shown benefit in PFS as mainte-
nance treatment after response to platinum based therapy in 
relapsed ovarian cancer. The magnitude of benefit is greater, 
but not limited, to patients with BRCA mutation. For BRCA 
-mutated patients maintenance treatment with olaparib 
improves PFS (HR 0.30) and OS (HR 0.74) with an improve-
ment of 12.9 months in median OS vs placebo. Niraparib 
and rucaparib have also shown positive results in phase III 
Table 3  Characteristics of patients and outcomes of phase III clinical trials with PARP inhibitors in first line
NACT neoadjuvant chemotherapy, HR hazard ratio, BRCA m BRCA mutated; BRCA wt BRCA wild type, HRD homologous recombination defi-
ciency, HRP homologous recombination proficiency, PDS primary debulking surgery, NA not Applicable, n.s. not significant







300 or 200 mg QD
Veliparib
150 BID C 1–6 and 400 mg BID 
cycle 7–36
Control arm Placebo Bevacizumab Placebo Placebo
Duration PARPi 2 years 2 years 3 years 36 cycles
(27 months)
FIGO
 Stage III 85–80% 69–70% 62–65% 77–78%
 Stage IV 15–20% 30–31% 34–38% 22–23%
NACT NR 41–42% 63–67% 26–29%
Residual disease 21–22% 29–41% 100% in stage III with PDS 30–32%






HR in overall population NA 0.59 0.62 0.68
HR in BRCA m 0.30 0.31 0.40 0.44
HR in HRD and BRCA wt NA 0.43 0.50 p = n.s.
HR in HRP NA p = n.s. 0.68 p = n.s.
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trials, not only in BRCA -mutated patients but also in BRCA 
wild type (wt), regardless the status of HR.
Therefore, when platinum might be the best option both 
platinum-based combination with bevacizumab and plati-
num-based combination followed by PARPi are optimal 
options [I, A]. Based on the higher RR with the addition of 
bevacizumab, this option would be indicated for sympto-
matic patients, without BRCA mutation, who did not receive 
bevacizumab at first line. For the rest of patients, platinum-
based combination followed by PARPi would be the pre-
ferred option [III, A]. For BRCA -mutated patients olaparib, 
niraparib or rucaparib can be used, and for BRCA wt patients 
niraparib or rucaparib are the available options [I, A].
If BRCA is mutated, monotherapy with rucaparib (not 
as maintenance) is also an alternative for patients with no 
previous PARPi treatment, who have been treated with two 
or more prior lines of platinum-based chemotherapy, and 
who are unable to tolerate further platinum-based chemo-
therapy [II, B].
In patients with TFIp > 6 months who cannot receive 
platinum-based therapy, or after previous use of PARPi and 
at least two platinum regimens, the combination trabectedin 
plus PLD could be an option [I, B].
Systemic treatment when platinum might not be 
the best option
Patients progressing on platinum-based therapy or after a 
short treatment-free interval of platinum are not considered 
eligible for re-challenge with platinum. This is an unmet 
medical need and when possible, patients should be included 
in clinical trials. Cytotoxic agents, such as weekly pacli-
taxel, PLD, gemcitabine and topotecan, have shown modest 
activity in phase III randomized trials, with an average RR 
of 10–15% and median OS in the range of 9–12 months. 
Accordingly, sequential cytotoxic single-agent therapy is the 
best palliative option and quality of life is the most impor-
tant endpoint. Nevertheless, patients with poor PS could be 
considered only for best supportive care.
For patients who have not received prior bevacizumab, 
the addition of the latter to weekly paclitaxel, PLD, or 
topotecan has shown to improve PFS. The combination 
weekly paclitaxel and bevacizumab was especially active in 
Aurelia trial, being the preferred option when possible [26].
In summary, when platinum might not be not the best 
option single-drug therapy, or in combination with bevaci-
zumab if not previously received, is recommended [I, A].
Follow‑up
Table 4 summarized our recommendations for follow-up. 
Although performing a routine imaging is controversial we 
recommended to do it at least every 6 months. It is important 
to review any new symptom reported by the patient and to 
perform a physical examination in each visit.
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follow-up recommendations
*In early-stage ovarian cancer these procedures could be performed every 6 months from the beginning
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treatment




Review of symptoms Every 3 months* Every 6 months Yearly
Physical examination Every 3 months* Every 6 months Yearly
Blood test + CA 125 Every 3 months* Every 6 months Yearly
CT scan Every 3–6 months Every 6 months Yearly
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